Hematologic Malignancy
Myeloid Leukemia
CI-CAN-00001251Explore in graph →
Hematologic862 active trials22 approved drugs599 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001251Explore in graph →
Clinical trials
3,530 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (619)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00326170 | Phase II 5-Azacytidine Plus VPA Plus ATRA | completed | Phase 2 | 34 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 15, 2012 | clinicaltrials |
| NCT00071006 | AG-013736 (Axitinib) In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS) | completed | Phase 2 | 12 | PfizerINDUSTRY | 1 | Jun 8, 2012 | clinicaltrials |
| NCT00111345 |
| Therapy-Optimization Trial for the Treatment of Acute Myeloid Leukemias (AML) in Children and Adolescents |
| unknown |
| Phase 2 / Phase 3 |
| 550 |
| University Hospital MuensterOTHER |
| 1 |
| May 23, 2012 |
| clinicaltrials |
| NCT00570999 | Palifermin After Haploidentical PBSCT(KGF Haplo Allo) | withdrawn | Phase 2 | 0 | European Society for Blood and Marrow TransplantationNETWORK | 1 | May 10, 2012 | clinicaltrials |
| NCT00081822 | Study of Clofarabine & Cytosine Arabinoside Therapy for Older Adults With Acute Myeloid Leukemia | completed | Phase 1 | 23 | University of Alabama at BirminghamOTHER | 1 | Apr 20, 2012 | clinicaltrials |
| NCT00719836 | A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies | completed | Phase 1 / Phase 2 | 76 | S*BIOINDUSTRY | 1 | Apr 20, 2012 | clinicaltrials |
| NCT01170598 | Acute Myeloid Leukaemia (AML) Patients Undergoing Induction Chemotherapy | completed | Phase 2 | 35 | Toronto Rehabilitation InstituteOTHER | 1 | Apr 20, 2012 | clinicaltrials |
| NCT00270881 | Safety and Efficacy of Unrelated Cord Blood Transplantation for Adult Patients With Hematologic Malignancies | completed | Phase 1 / Phase 2 | 33 | Keio UniversityOTHER | 1 | Apr 6, 2012 | clinicaltrials |
| NCT00981240 | Dose Escalation, Safety and Pharmacokinetic Study of SAR103168 in Patients Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes | completed | Phase 1 | 30 | SanofiINDUSTRY | 1 | Mar 27, 2012 | clinicaltrials |
| NCT00887042 | Study of Reduced Toxicity Myeloablative Conditioning Regimen for Cord Blood Transplantation in Pediatric AML | unknown | Phase 1 / Phase 2 | 35 | The Korean Society of Pediatric Hematology OncologyNETWORK | 1 | Mar 26, 2012 | clinicaltrials |
| NCT00333190 | CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation | completed | N/A | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 16, 2012 | clinicaltrials |
| NCT01556477 | The Efficacy of Azacitidine +/- Lenalidomide in High-risk Myelodysplastic Syndrome (MDS)and Acute Myeloid Leukemia (AML) With Del(5q). | unknown | Phase 2 | 72 | Nordic MDS GroupNETWORK | 1 | Mar 16, 2012 | clinicaltrials |
| NCT01066468 | Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders. | terminated | Phase 1 | 3 | Novartis PharmaceuticalsINDUSTRY | 1 | Mar 13, 2012 | clinicaltrials |
| NCT00799461 | Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications | completed | Phase 3 | 1,337 | Fred Hutchinson Cancer Research Center/University of Washington Cancer ConsortiumOTHER | 1 | Mar 7, 2012 | clinicaltrials |
| NCT00101660 | Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib | completed | Phase 2 | 387 | Bristol-Myers SquibbINDUSTRY | 22 | Mar 2, 2012 | clinicaltrials |
| NCT00445822 | Registration of Children With CML and Treatment With Imatinib(CML-paed II) | unknown | — | 150 | Technische Universität DresdenOTHER | 1 | Feb 29, 2012 | clinicaltrials |
| NCT01452334 | Safety Study of Anti-Programmed Death-Ligand 1 in Hematologic Malignancy | withdrawn | Phase 1 | 0 | Bristol-Myers SquibbINDUSTRY | 0 | Feb 23, 2012 | clinicaltrials |
| NCT00074750 | Study of DT388GMCSF Fusion Protein in Acute Myelogenous Leukemia (AML) and Chronic Myelomonocytic Leukemia (CMML) | terminated | Phase 1 | 7 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 22, 2012 | clinicaltrials |
| NCT00493181 | Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) Patients | completed | Phase 2 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 20, 2012 | clinicaltrials |
| NCT01534702 | Dose Escalation of Clofarabine in Combination With Cytarabine and Idarubicin as Induction Therapy in High Risk AML(CIARA) | unknown | Phase 1 / Phase 2 | 60 | Hannover Medical SchoolOTHER | 1 | Feb 20, 2012 | clinicaltrials |
| NCT01180426 | Extension Study With Tosedostat in Relapsed/Refractory Acute Myeloid Leukemia | unknown | Phase 2 | 30 | Chroma TherapeuticsINDUSTRY | 1 | Feb 15, 2012 | clinicaltrials |
| NCT00764231 | A Study of a Home-based Exercise Intervention for Patients With Acute Myeloid Leukaemia (AML) | completed | Phase 2 | 40 | Toronto Rehabilitation InstituteOTHER | 1 | Feb 8, 2012 | clinicaltrials |
| NCT00144677 | Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation | completed | Phase 2 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 26, 2012 | clinicaltrials |
| NCT00144703 | Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell Transplantation | completed | Phase 2 | 55 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 26, 2012 | clinicaltrials |
| NCT00795548 | Safety Study of 5-Azacitidine and Standard Donor Lymphocyte Infusion (DLI) to Treat Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing After Allogeneic Stem Cell Transplantation | completed | Phase 2 | 30 | Heinrich-Heine University, DuesseldorfOTHER | 1 | Jan 23, 2012 | clinicaltrials |
| NCT00088231 | PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP | completed | Phase 1 / Phase 2 | 9 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 20, 2012 | clinicaltrials |
| NCT01513109 | Safety and Immunogenicity of Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic Combined With Infusion of Treg Depleted T Cells for Adult WT1 Acute Myeloid Leukemia(ASCI) | unknown | Phase 1 / Phase 2 | 20 | Jules Bordet InstituteOTHER | 1 | Jan 20, 2012 | clinicaltrials |
| NCT01513603 | Trial of Cladribine, Cytarabine, Mitoxantrone, Filgrastim (CLAG-M) in Relapsed Acute Lymphoblastic Leukemia | unknown | Phase 2 | 50 | New York Medical CollegeOTHER | 1 | Jan 20, 2012 | clinicaltrials |
| NCT00895297 | Efficacy and Safety Study of Dasatinib in Patients With Chronic Myeloid Leukemia(Dasatinib) | terminated | Phase 2 | 50 | European Society for Blood and Marrow TransplantationNETWORK | 4 | Dec 7, 2011 | clinicaltrials |
| NCT01374139 | Bioequivalence And Food Effect Study Of Bosutinib In Healthy Subjects | completed | Phase 1 | 88 | PfizerINDUSTRY | 1 | Nov 30, 2011 | clinicaltrials |
| NCT00519090 | Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)(ENEST) | terminated | Phase 3 | 6 | Novartis PharmaceuticalsINDUSTRY | 10 | Nov 7, 2011 | clinicaltrials |
| NCT01464411 | Dasatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia in Japan(D-First) | unknown | — | 40 | Kanto CML Study GroupOTHER | 1 | Nov 3, 2011 | clinicaltrials |
| NCT01003054 | Autologous Transplantation for Chronic Myelogenous Leukemia | completed | Phase 2 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 2, 2011 | clinicaltrials |
| NCT00763763 | Imatinib Mesylate With Vincristine and Dexamethasone in Acute Lymphoblastic Leukemias With BCR-ABL Positive(AFR07) | completed | Phase 2 | 55 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Oct 5, 2011 | clinicaltrials |
| NCT01011998 | A Study of Imatinib and Valproic Acid in Patients With Chronic Myelogenous Leukemia (CML) | withdrawn | Phase 2 | 0 | New Mexico Cancer Research AllianceOTHER | 1 | Sep 27, 2011 | clinicaltrials |
| NCT00430443 | Liposomal Annamycin in Children and Young Adults With Refractory or Relapsed ALL or AML | terminated | Phase 1 | 3 | Callisto PharmaceuticalsINDUSTRY | 1 | Aug 31, 2011 | clinicaltrials |
| NCT01423175 | ClAraC or FLAMSA Followed by Stem Cell Transplantation to Treat High Risk AML or Advanced MDS(ClAraC-SCT) | unknown | Phase 2 | 60 | Hannover Medical SchoolOTHER | 1 | Aug 29, 2011 | clinicaltrials |
| NCT00302016 | Expanded Access Program of AMN107 in Imatinib-resistant or Intolerant Adult Patients With Chronic Myeloid Leukemia | no longer available | — | — | Novartis PharmaceuticalsINDUSTRY | 34 | Aug 26, 2011 | clinicaltrials |
| NCT00969891 | Study of Dosage Individualisation for the Treatment of Acute Myeloid Leukemia | completed | — | 23 | Mikkel Krogh-MadsenOTHER | 1 | Aug 25, 2011 | clinicaltrials |
| NCT01414231 | Comparison of the OSHO Protocol to a Standard Arm Protocol of the German AML Intergroup in Patients With AML<60a(OSHO#061) | unknown | Phase 3 | 850 | University of LeipzigOTHER | 1 | Aug 11, 2011 | clinicaltrials |
| NCT00760084 | Trial of Decitabine in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome | completed | Phase 2 | 10 | Eisai Inc.INDUSTRY | 1 | Aug 8, 2011 | clinicaltrials |
| NCT00839059 | Lenalidomide In Patients With Acute Myeloid Leukemia | terminated | Phase 1 | 14 | University of UlmOTHER | 1 | Jul 29, 2011 | clinicaltrials |
| NCT00413270 | Oral Nilotinib in Adults With Chronic Myeloid Leukemia (CML) in Blast Crisis Who Are Imatinib Resistant or Intolerant | no longer available | — | — | Novartis PharmaceuticalsINDUSTRY | 1 | Jul 13, 2011 | clinicaltrials |
| NCT00422890 | Treatment of Imminent Haematological Relapse in Patients With AML and MDS Following Allogeneic Stem Cell Transplantation With 5-azacitidine (Vidaza®) | completed | Phase 3 | 10 | Technische Universität DresdenOTHER | 1 | Jul 11, 2011 | clinicaltrials |
| NCT00538876 | Phase I Epigenetic Priming Using Decitabine With Induction Chemotherapy in AML | completed | Phase 1 | 30 | Weill Medical College of Cornell UniversityOTHER | 1 | Jun 30, 2011 | clinicaltrials |
| NCT00926731 | Study to Assess the Safety and Tolerability of AZD1152 in Combination With Low Dose Cytosine Arabinoside (LDAC) | completed | Phase 1 | 4 | AstraZenecaINDUSTRY | 2 | Jun 16, 2011 | clinicaltrials |
| NCT00474006 | High Dose Daunorubicin Vs. Standard Dose Daunorubicin in Induction Treatment of AML(ADcomparison) | completed | Phase 3 | 398 | Cooperative Study Group A for HematologyNETWORK | 1 | Jun 10, 2011 | clinicaltrials |
| NCT00521664 | A Trial Comparing a Prophylactic With a Therapeutic Platelet Transfusion Strategy in Two Groups | completed | Phase 3 | 400 | Technische Universität DresdenOTHER | 1 | May 19, 2011 | clinicaltrials |
| NCT00339196 | 5-azacytidine Valproic Acid and ATRA in AML and High Risk MDS | completed | Phase 2 | 25 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 9, 2011 | clinicaltrials |
Data updated 23 days agoSource updated Jun 15, 2012source: clinicaltrials